Ascentage Pharma Group International – Unsponsored ADR (AAPG) – What Are Researchers Thinking About This Stock?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned a consensus recommendation of “Buy” from the fourteen ratings firms that are currently covering the company, MarketBeat reports. Twelve research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $43.90.

AAPG has been the subject of several recent research reports. Citizens Jmp initiated coverage on Ascentage Pharma Group International in a report on Tuesday. They set a “market outperform” rating and a $35.00 price target for the company. Citigroup assumed coverage on shares of Ascentage Pharma Group International in a report on Tuesday. They issued a “buy” rating and a $46.00 target price on the stock. JPMorgan Chase & Co. dropped their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. William Blair assumed coverage on Ascentage Pharma Group International in a research note on Friday. They set an “outperform” rating for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st.

Ascentage Pharma Group International Price Performance

NASDAQ AAPG opened at $14.69 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. Ascentage Pharma Group International has a one year low of $14.45 and a one year high of $37.50. The firm’s fifty day moving average is $16.55 and its two-hundred day moving average is $19.11.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million for the quarter. On average, analysts forecast that Ascentage Pharma Group International will post -2.42 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.